Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early-phase Clinical Study on Safety, Tolerability and Preliminary Efficacy of ART002g1 Injection in the Treatment of Heterozygous Familial Hypercholesterolemia

NCT07353398 is registered in ClinicalTrials.gov with Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine as lead sponsor.

NCT NCT07353398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07353398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early-phase Clinical Study on Safety, Tolerability and Preliminary Efficacy of ART002g1 Injection in the Treatment of Heterozygous Familial Hypercholesterolemia
Lead sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase
Phase 1
Overall status
Not yet recruiting
Start date
March 11, 2026
Completion date
July 31, 2027
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heterozygous familial hypercholesterolemia